HRSA-21-096: Quality Improvement Solutions for Sustained Epidemic Control Project (QISSEC)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Health Resources and Services Administration notices from 2021.
Health Resources and Services Administration offered grants to the applicants described in the notice. It expected to make about 2 awards worth $20.0 million in total. Applications closed on May 7, 2021.
From the official notice on Grants.gov, last changed March 8, 2021. Checked November 7, 2026.
- Total funding$20.0 million
- Expected awards2
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | March 8, 2021 |
|---|---|
| Deadline | May 7, 2021 |
| Archived by Grants.gov | July 6, 2021 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligible applicants include domestic or foreign public or non-profit private entities, including schools of medicine, nursing, public health, management and public administration, and academic health centers, community-based organizations, faith- based organizations, and consortia consisting of such eligible organizations.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
This notice announces the opportunity to apply for funding for the Quality Improvement Solutions for Sustained Epidemic Control Project (QISSEC). The purpose of this project is to facilitate improvements in quality across the HIV care continuum at the site level (defined as the location where persons diagnosed with HIV receive care and treatment) and within the community. The project attempts to improve the effectiveness, efficiency, patient-centeredness, safety, accessibility, and equity of the HIV services in low to middle-income countries (LMIC) as identified by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) program. FY21 PEPFAR priorities recognize quality health services as essential in order to ensure that optimal health outcomes are met on a daily and routine basis. Therefore, all PEPFAR country programs must incorporate explicit quality management (QM) practices, including both quality assurance (QA) and quality improvement (QI) activities into service delivery and partner management. Focused on building the capacity of countries to sustain and spread QI methodologies, improve documentation of efforts, and continuously enhance staff knowledge, QISSEC strives to impact the delivery of quality HIV services, improve health outcomes, and support HIV/AIDS epidemic control. This Notice of Funding Opportunity (NOFO) will fund two cooperative agreements in support of the PEPFAR focus on the management of evidence-informed interventions for scale-up and spread. The successful applicants will facilitate solutions for long-term change management approaches and sustainability of QA and QI activity. The QISSEC shall focus on developing innovative strategies to improve the delivery of HIV quality care and treatment for use by facilities that serve the most vulnerable individuals in PEPFAR-supported LMICs. Using quality improvement methodologies, tools, and techniques, the project will identify gaps in service delivery, and develop culturally and medically appropriate, sustainable interventions targeted to PEPFAR- identified vulnerable and key populations. Over 18 years PEPFAR https://www.state.gov/pepfar/ has evolved to a complex and high impact program, with mature stakeholders and partners showing that epidemic control is indeed possible.
Who has won Health Systems Strengthening and HIV/AIDS Prevention, Care and Treatment under the President's Emergency Plan for AIDS Relief grants before
From fiscal 2021 to 2025, Health Systems Strengthening and HIV/AIDS Prevention, Care and Treatment under the President's Emergency Plan for AIDS Relief (93.266) awarded $129 million across 16 grant awards, an average of $8.1 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Washington | Washington | 3 | $53.8 million |
| Jhpiego Corp | Maryland | 4 | $34.4 million |
| Meharry Medical College | Tennessee | 1 | $25.8 million |
| The Regents of the University of California, San Francisco | California | 2 | $7.5 million |
| The Trustees of Columbia University in the City of New York | New York | 3 | $4.0 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-21-096 still open?
No. It closed on May 7, 2021.
Who can apply for Quality Improvement Solutions for Sustained Epidemic Control Project (QISSEC)?
Health Resources and Services Administration accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Quality Improvement Solutions for Sustained Epidemic Control Project (QISSEC)?
Closed May 7, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $20.0 million in total across about 2 awards.
Who has won Health Systems Strengthening and HIV/AIDS Prevention, Care and Treatment under the President's Emergency Plan for AIDS Relief grants before?
The largest recipients over five fiscal years were University of Washington, Jhpiego Corp, Meharry Medical College. The program made 16 awards worth $129 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)